Development of the Harvey-Bradshaw Index-pro (HBI-PRO) Score to Assess Endoscopic Disease Activity in Crohn’s Disease

Background There is a need for better, less-invasive disease activity indices that provide a representative assessment of endoscopic disease activity. We developed a new clinical score that incorporates the Harvey-Bradshaw index [HBI] with modified patient-reported outcomes [PROp] and physician [clinician]-reported outcomes [PROc] and assessed its ability to measure endosopic disease activity in ileocolonic Crohn's disease [CD]. Methods A cohort of 88 CD patients undergoing colonoscopy was accrued in a prospective fashion. In total, 48 of the subjects were CD cases and 40 had already undergone a post-operative ileocolonic resection [post-op CD]. Each patient underwent multiple, endoscopist-blinded assessments including: HBI score, a PROp question asking for patient perception of disease activity status, a PROc question for clinician perception of disease activity status and C-reactive protein [CRP]. Active endoscopic disease was defined as Simple Endoscopic Score for CD [SES-CD] ≥ 3 for CD subjects and Rutgeerts score > i1 for post-op CD subjects. Results Clinical remission as defined by the HBI did not accurately reflect endoscopic remission as defined by the SES-CD (area under the curve [AUC] = 0.54). Combining the HBI with PROp and PROc scores and then further adding CRP significantly improved the correlation with SES-CD [AUC = 0.78 and AUC = 0.88, respectively, p < 0.00001]. In post-op CD, HBI-defined remission also performed poorly against endoscopic remission defined by the Rutgeerts score [AUC = 0.52]. Combining HBI with PROp and the PROc scores and then further adding CRP did not significantly improve the model [AUC = 0.65 and AUC = 0.61, respectively, p = NS]. Conclusion In CD, the HBI correlates poorly with endoscopic disease activity. However, the HBI-PRO score, which incorporated PROp, PROc, CRP and HBI, significantly improved its ability to predict endoscopic activity in ileocolonic CD without prior surgery.

[1]  S. Hanauer,et al.  Treat to target: a proposed new paradigm for the management of Crohn's disease. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  M. Vandervoort,et al.  A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity , 2015, Alimentary pharmacology & therapeutics.

[3]  L. Peyrin-Biroulet,et al.  Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  L. Peyrin-Biroulet,et al.  Histologic remission: the ultimate therapeutic goal in ulcerative colitis? , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  J. Fletcher,et al.  EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study Identifies Fecal Calprotectin, Serum MMP9, and Serum IL-22 as a Novel Combination of Biomarkers for Crohn's Disease Activity: Role of Cross-Sectional Imaging , 2013, The American Journal of Gastroenterology.

[6]  C. Polman,et al.  Analyzing differences between patient and proxy on Patient Reported Outcomes in multiple sclerosis , 2013, Journal of the Neurological Sciences.

[7]  K. Bodger,et al.  Development and validation of a rapid, generic measure of disease control from the patient's perspective: the IBD-Control questionnaire , 2013, Gut.

[8]  A. Shields,et al.  Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Acaster,et al.  Methods for interpreting change over time in patient-reported outcome measures , 2013, Quality of Life Research.

[10]  S. Vermeire,et al.  Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease , 2012, Inflammatory bowel diseases.

[11]  C. Sánchez-Montes,et al.  Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients. , 2012, World journal of gastroenterology.

[12]  C. Polman,et al.  Proxy measurements in multiple sclerosis: agreement on different patient-reported outcome scales , 2012, Multiple sclerosis.

[13]  L. Peyrin-Biroulet,et al.  Surgery for adult Crohn's disease: what is the actual risk? , 2011, Gut.

[14]  E. Kuipers,et al.  Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation , 2011, Inflammatory bowel diseases.

[15]  M. Färkkilä,et al.  Endoscopic evaluation of Crohn's disease activity: Comparison of the CDEIS and the SES‐CD† , 2010, Inflammatory bowel diseases.

[16]  Stefan Schreiber,et al.  Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[17]  J. Ellenberg,et al.  Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative Colitis , 2008, Inflammatory bowel diseases.

[18]  A. Zinsmeister,et al.  Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[19]  V. Strand,et al.  Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. , 2008, Arthritis and rheumatism.

[20]  M. Schwartz,et al.  The quantitative validation of non‐endoscopic disease activity indices in ulcerative colitis , 2006, Alimentary pharmacology & therapeutics.

[21]  J. Satsangi,et al.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications , 2006, Gut.

[22]  M. Schwartz,et al.  Is Endoscopy Necessary for the Measurement of Disease Activity in Ulcerative Colitis? , 2005, The American Journal of Gastroenterology.

[23]  P. Rutgeerts,et al.  A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. , 2002, Gastroenterology.

[24]  P. Rutgeerts,et al.  Predictability of the postoperative course of Crohn's disease. , 1990, Gastroenterology.

[25]  H. Verspaget,et al.  Are activity indices helpful in assessing active intestinal inflammation in Crohn's disease? , 1989, Gut.

[26]  C. Smith,et al.  Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. , 1986, Gut.

[27]  R. F. Harvey,et al.  A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY , 1980, The Lancet.

[28]  F Kern,et al.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. , 1976, Gastroenterology.

[29]  B. Sands,et al.  Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. , 2015, Gastroenterology.

[30]  I. Brandslund,et al.  How accurate are clinical activity indices for scoring of disease activity in inflammatory bowel disease (IBD)? , 2005, Clinical chemistry and laboratory medicine.

[31]  A. Cieza,et al.  Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health , 2022 .